Logo
x

Search

Subscribe Now

Lundbeck

Lundbeck to Acquire Longboard Pharmaceuticals, Strengthening its Neuroscience Portfolio

Lundbeck to Acquire Longboard Pharmaceuticals, Strengthening its Neuroscience Portfolio

  • October 15, 2024
Rami Apelian and Marija Geertsen Share Insights from 9 Poster Presentations on Migraine Prevention & Treatment at AHS 2022

Rami Apelian and Marija Geertsen Share Insights from 9 Poster Presentations on Migraine Prevention & Treatment at AHS 2022

  • August 29, 2022
Lundbeck’s Vyepti (eptinezumab) Receives EC’s Approval for the Treatment of Migraine

Lundbeck’s Vyepti (eptinezumab) Receives EC’s Approval for the Treatment of Migraine

  • January 25, 2022
PharmaShots Weekly Snapshots (June 14 - 18, 2021)

PharmaShots Weekly Snapshots (June 14 - 18, 2021)

  • June 18, 2021
Lundbeck Halts P-II Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia

Lundbeck Halts P-II Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia

  • August 6, 2020
Insights+: The US FDA New Drug Approvals in February 2020

Insights+: The US FDA New Drug Approvals in February 2020

  • March 27, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.